よむ、つかう、まなぶ。
参考資料３ WHO Statement on the antigen composition of COVID-19 vaccines (4 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/newpage_00104.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチンの製造株について検討する小委員会（第2回 5／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
symptomatic disease and infection is lower and wanes more rapidly over
several months.
o Monovalent XBB.1.5 vaccines were introduced into some vaccination
programmes in the last quarter of 2023. Protection against severe disease
durind Deriods of XBB descendent lineage circulation is high during the
first three months after vaccination, but protection against symptomatic
disease IS lOwer.
o There are fewer studies estimating rVE for the monovalent XBB.1.5 vaccines
durind Deriods of」N.1 descendent lineage circulation. These initial studies
show some additional protection offered during the first three months
after vaccination, but point towards a slight reduction in VE against 」N.1, as
Compared to XBB.1 lineage variants, for protection against severe and
Symptomatic disease. These observations are consistent with reductions in
neutralizing antibody titres observed in preclinical and clinical
immunogenicity studies of monovalent XBB.1.5 vaccinee sera against 」N.1
derived variantS.
Preclinical data shared confidentially with the TAG-CO-VAC by vaccine
manufacturers show that immunization of nalve mice, as well as mice previousIly
immunized with SARS-CoV-2 variants, with monovalent」N.1-containing vaccine
candidates elicits higher neutralizing antibody responses to 」N.1 and its emergind
descendent variants, as Compared to resDonSses elicited by currently approved
Vaccines. A single irmmunogenicity study in humans of a monovalent 」N.1-
containindg vaccine candidate sugdgests that a 」N.1 vaccine antigen is likely to
produce higher neutralising antibodies to co-circulating 」N.1 variants (e.q., KP.2)
than an XBB.1.5 or related vaccine antigen.
The TAG-CO-VAC acknowledges several limitations of the available data:
There are persistent and increasing daps in genetic/genomic surveillance of
SARS-CoV-2 globally, including low numbers of samples seduenced and limited
geodgraphic diversity. The TAG-CO-VAC strongly supports the establishment of the
WHO Coronavirus Network (CoViNet) to help address this information gaD.
The trajectory of further SARS-CoV-2 evolution indicates that 」N.1 will likely be the
progenitor of SARS-CoV-2 variants, in the near term. However, the tirming, SDecific
mutations and antigenic characteristics, and the potential public health impact of
newly emerged (e.q. KP.2) and future variants remain unknown. The TAG-CO-VAC
strondly suDDorts the ongoing work of the TAG-VE.
several months.
o Monovalent XBB.1.5 vaccines were introduced into some vaccination
programmes in the last quarter of 2023. Protection against severe disease
durind Deriods of XBB descendent lineage circulation is high during the
first three months after vaccination, but protection against symptomatic
disease IS lOwer.
o There are fewer studies estimating rVE for the monovalent XBB.1.5 vaccines
durind Deriods of」N.1 descendent lineage circulation. These initial studies
show some additional protection offered during the first three months
after vaccination, but point towards a slight reduction in VE against 」N.1, as
Compared to XBB.1 lineage variants, for protection against severe and
Symptomatic disease. These observations are consistent with reductions in
neutralizing antibody titres observed in preclinical and clinical
immunogenicity studies of monovalent XBB.1.5 vaccinee sera against 」N.1
derived variantS.
Preclinical data shared confidentially with the TAG-CO-VAC by vaccine
manufacturers show that immunization of nalve mice, as well as mice previousIly
immunized with SARS-CoV-2 variants, with monovalent」N.1-containing vaccine
candidates elicits higher neutralizing antibody responses to 」N.1 and its emergind
descendent variants, as Compared to resDonSses elicited by currently approved
Vaccines. A single irmmunogenicity study in humans of a monovalent 」N.1-
containindg vaccine candidate sugdgests that a 」N.1 vaccine antigen is likely to
produce higher neutralising antibodies to co-circulating 」N.1 variants (e.q., KP.2)
than an XBB.1.5 or related vaccine antigen.
The TAG-CO-VAC acknowledges several limitations of the available data:
There are persistent and increasing daps in genetic/genomic surveillance of
SARS-CoV-2 globally, including low numbers of samples seduenced and limited
geodgraphic diversity. The TAG-CO-VAC strongly supports the establishment of the
WHO Coronavirus Network (CoViNet) to help address this information gaD.
The trajectory of further SARS-CoV-2 evolution indicates that 」N.1 will likely be the
progenitor of SARS-CoV-2 variants, in the near term. However, the tirming, SDecific
mutations and antigenic characteristics, and the potential public health impact of
newly emerged (e.q. KP.2) and future variants remain unknown. The TAG-CO-VAC
strondly suDDorts the ongoing work of the TAG-VE.